Rewiring commercialisation to meet the moment, with Helen Sabzevari and Greg Skalicky

New modalities in treatment call for many process changes for commercialisation. And these changes can hit smaller biotechs harder than larger, better-resourced organisations.

At the Informa Biotech Showcase during JP Morgan Week in San Francisco, editor-in-chief Jonah Comstock caught up with EVERSANA President Greg Skalicky and Helen Sabzevari, CEO of Precigen, to talk about this new commercialisation world and how organisations can tackle it.

They discuss how 70% of launches fail to meet first-year expectations, why that is, and why it can be particularly detrimental in smaller indications like rare disease. And they go into the benefits of matching commercialisation strategies to development strategies to optimise resources across shorter timelines.

There’s also some discussion of trends in AI and an update on Precigen’s treatment for the rare disease recurrent respiratory papillomatosis. Check out the video to learn more about how commercialisation is changing to meet biotech’s new challenges and opportunities. 

Watch this and other conversations from JPM2026 here.